GOSS
Gossamer Bio, Inc.
Next earnings Aug 3, 2026 (before open) · consensus $-0.13 EPS, $5.26M rev
Last earnings -43.2% on 2026-05-18
$0.16
▼ -4.96%$0.16▼ -89.10%
over 1Y
L $0.16EODHDH $3.79
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-5.0%
1W-4.4%
1M-28.0%
3M-54.8%
YTD-94.5%
1Y-89.1%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 14 analysts
Buy
Conservative balance sheet (liabilities/equity -2.40x); but revenue fell -57.7% YoY.
Gossamer Bio, Inc. shows $48.5M in FY2025 revenue (-57.7% YoY), a -351.5% net margin.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $115M | $48.5M |
| Gross profit | — | — | — | — | — |
| Operating income | -$216M | -$219M | -$184M | -$59.9M | -$171M |
| Net income | -$234M | -$229M | -$180M | -$56.5M | -$170M |
| Diluted EPS | -$3.13 | -$2.71 | -$1.18 | -$0.25 | -$0.75 |
| Net margin | — | — | — | -49.3% | -351.5% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value-$885K
EV / EBITDA—
EV / Sales-0.0
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-462.4%
FCF yield-465.0%
Quality & risk
ROIC (est.)—
Free cash flow-$171M
Total debt$0.00
Net cash$37.7M
Altman Z-Score-13.88 distress
Piotroski F-Score1/8
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+3.3%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — agreement terminated (2026-06-05). Worth a closer look.
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-172026-06-17open ↗SCHEDULE 13DFiling2026-06-11open ↗SCHEDULE 13GFiling2026-06-11open ↗SCHEDULE 13GFiling2026-06-11open ↗DEF 14APeriod ending 2026-07-142026-06-09open ↗SCHEDULE 13GFiling2026-06-09open ↗4Period ending 2026-06-042026-06-05open ↗4Period ending 2026-06-042026-06-05open ↗4Period ending 2026-06-042026-06-05open ↗4Period ending 2026-06-042026-06-05open ↗4Period ending 2026-06-042026-06-05open ↗4Period ending 2026-06-042026-06-05open ↗
Frequently asked
- Is Gossamer Bio, Inc. (GOSS) a buy?
- GOSS currently carries a Avoid rating with 4/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity -2.40x); but revenue fell -57.7% YoY.
- What is Gossamer Bio, Inc.'s quality score?
- GOSS scores 35.88235294117647/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001728117, latest 10-Q filed 2026-05-15) · EODHD · as of 6/25/2026, 6:09:10 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.